Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM9AGWQ)

• Drug Name: HEXESTROL Drug Info
• Synonyms: hexestrol; Dihydrodiethylstilbestrol; Vitestrol; Hexoestrolum; Exestrol; 5635-50-7; Stilbestrol, dihydro-; 4,4'-(1,2-Diethylethylene)diphenol; 4,4'-(hexane-3,4-diyl)diphenol; Synoestrolum; Hexanestrol; Cycloestrol; Esestrolo [DCIT]; Phenol, 4,4'-(1,2-diethyl-1,2-ethanediyl)bis-; Hexestrolum [INN-Latin]; Hexane, 3,4-bis(4-hydroxyphenyl)-; EINECS 227-082-2; 3,4-Bis(p-hydroxyphenyl)hexane; Hormoestrol; Syntrogene; Synthovo; Phenol, 4,4'-(1,2-diethylethylene)di-; CHEBI:31669; PBBGSZCBWVPOOL-UHFFFAOYSA-N; Hexestrol [INN]

Indication

Disease Entry	ICD 11	Status	REF
Irregularities	N.A.	Withdrawn from market	[1]

• Cross-matching ID:
  PubChem CID: 3606
  ChEBI ID: CHEBI:31669
  CAS Number: CAS 5635-50-7
  TTD Drug ID: DM9AGWQ

Molecule-Related Drug Atlas

Drug(s) Targeting Estrogen receptor beta (ESR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Conjugated Estrogens	DMLT0E1	Dyspareunia	GA12	Approved	[5]
Trilostane	DMQZ9GF	Cushing disease	5A70	Approved	[6]
ARZOXIFENE	DMOKCVI	Breast cancer	2C60-2C65	Approved	[7]
Estrogen	DMGY0UT	Menopause symptom	GA30.0	Approved	[8]
MF-101	DM8Z0I3	Hepatitis virus infection	1E50-1E51	Phase 3	[9]
Genistein	DM0JETC	Menopause symptom	GA30.0	Phase 2/3	[10]
AUS-131	DMUXO3Z	Hot flushes	GA30	Phase 2	[11]
ERB-041	DMCEPUA	Inflammatory bowel disease	DD72	Phase 2	[12]
Erteberel	DMU1XZD	Prostate hyperplasia	GA90	Phase 2	[13]
VG-101	DMAN21O	Menopause symptom	GA30.0	Phase 1/2	[14]

Drug(s) Targeting Estrogen receptor (ESR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[15]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[16]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[16]
Estradiol Valerate	DM8MC6O	Hormone replacement therapy	8E01	Approved	[6]
Estradiol Acetate	DM07U2A	Hormone replacement therapy	8E01	Approved	[6]
Estradiol Cypionate	DM27Z5T	Hormone replacement therapy	8E01	Approved	[6]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[17]
Raloxifene	DMDKF3M	Osteoporosis	FB83.0	Approved	[18]
Ospemifene	DMC4GEI	Dyspareunia	GA12	Approved	[19]
Toremifene	DMQYUWG	Breast cancer	2C60-2C65	Approved	[20]

Drug(s) Affected By Aldo-keto reductase family 1 member C4 (AKR1C4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Meclofenamic acid	DM05FXR	Ankylosing spondylitis	FA92.0	Approved	[21]
Diazepam	DM08E9O	Alcohol withdrawal		Approved	[22]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[23]
Benzbromarone	DMC3YUA	Gout	FA25	Approved	[3]
Flufenamic Acid	DMC8VNH	Dysmenorrhea	GA34.3	Approved	[3]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[24]
Nitrazepam	DMEGIQ6	Epilepsy	8A60-8A68	Approved	[22]
Flunitrazepam	DMGR5Z3	Insomnia	7A00-7A0Z	Approved	[22]
Chenodiol	DMQ8JIK	Cholelithiasis	DC11	Approved	[25]
Gamolenic acid	DMQN30Z	Allergy	4A80-4A85	Approved	[26]

Drug(s) Affected By Aldo-keto reductase family 1 member C3 (AKR1C3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[27]
Meclofenamic acid	DM05FXR	Ankylosing spondylitis	FA92.0	Approved	[28]
Diazepam	DM08E9O	Alcohol withdrawal		Approved	[22]
Levonorgestrel	DM1DP7T	Atypical endometrial hyperplasia		Approved	[29]
Desogestrel	DM27U4Y	Contraception	QA21	Approved	[29]
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[28]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[28]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[30]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[31]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[32]

Drug(s) Affected By Aldo-keto reductase family 1 member C2 (AKR1C2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Meclofenamic acid	DM05FXR	Ankylosing spondylitis	FA92.0	Approved	[28]
Diazepam	DM08E9O	Alcohol withdrawal		Approved	[22]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[33]
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[34]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[28]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[35]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[36]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[28]
Liothyronine	DM6IR3P	Congenital hypothyroidism		Approved	[37]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[38]

Drug(s) Affected By Aldo-keto reductase family 1 member C1 (AKR1C1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[39]
Meclofenamic acid	DM05FXR	Ankylosing spondylitis	FA92.0	Approved	[28]
Diazepam	DM08E9O	Alcohol withdrawal		Approved	[22]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[40]
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[28]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[28]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[41]
Glimepiride	DM5FSJA	Diabetic complication	5A2Y	Approved	[42]
Ethacrynic acid	DM60QMR	Edema	MG29	Approved	[40]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[28]

Drug(s) Affected By Sulfotransferase 1E1 (SULT1E1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Meclofenamic acid	DM05FXR	Ankylosing spondylitis	FA92.0	Approved	[43]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[43]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[44]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[45]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[43]
Dienestrol	DMBSXI0	Atrophic vaginitis	GA30.2	Approved	[45]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[46]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[47]
Bosentan	DMIOGBU	Pulmonary arterial hypertension	BB01.0	Approved	[48]
Sodium lauryl sulfate	DMLJ634	Constipation	DD91.1	Approved	[49]

Drug(s) Affected By Serine/threonine-protein kinase Sgk1 (SGK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[4]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[50]
Spironolactone	DM2AQ5N	Chronic heart failure	BD1Z	Approved	[51]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[52]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[35]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[32]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[53]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[4]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[54]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[55]

Drug(s) Affected By Prostaglandin E synthase (PTGES)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[4]
Selenium	DM25CGV	N. A.	N. A.	Approved	[56]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[57]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[58]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[59]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[24]
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[60]
Mestranol	DMG3F94	Contraception	QA21	Approved	[4]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[61]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[62]

Drug(s) Affected By E3 ubiquitin-protein ligase SIAH2 (SIAH2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[4]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[63]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[64]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[4]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[65]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[66]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[67]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[67]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[23]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[24]

Drug(s) Affected By Carbonic anhydrase 12 (CA12)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetazolamide	DM1AF5U	Absence epilepsy		Approved	[68]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[4]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[69]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[70]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[71]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[4]
Topiramate	DM82Z30	Alcohol dependence	6C40.2	Approved	[72]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[73]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[23]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[74]

Drug(s) Affected By Tyrosine-protein kinase JAK2 (JAK2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Momelotinib	DMF98Q0	Myelofibrosis	2A20.2	Approved	[75]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[4]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[76]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[35]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[64]
Paroxetine	DM5PVQE	Anxiety disorder	6B00-6B0Z	Approved	[77]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[4]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[78]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[23]
Amlodipine	DMBDAZV	Angina pectoris	BA40	Approved	[79]

Drug(s) Affected By Serine protease 23 (PRSS23)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[80]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[81]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[71]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[4]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[55]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[82]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[82]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[23]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[74]
Palbociclib	DMD7L94	Breast cancer	2C60-2C65	Approved	[83]

Drug(s) Affected By Supervillin (SVIL)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[80]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[84]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[85]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[64]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[4]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[23]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[86]
Mestranol	DMG3F94	Contraception	QA21	Approved	[4]
Mifepristone	DMGZQEF	Cushing disease	5A70	Approved	[87]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[88]

Drug(s) Affected By Transcription factor AP-2-alpha (TFAP2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[89]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[4]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[90]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[91]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[71]
Paroxetine	DM5PVQE	Anxiety disorder	6B00-6B0Z	Approved	[89]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[38]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[92]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[67]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[67]

Drug(s) Affected By Progesterone receptor (PGR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[93]
Drospirenone	DM1A9W3	Acne vulgaris	ED80	Approved	[94]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[95]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[96]
Tibolone	DM78XFG	Anabolic metabolism	5C50-5C8Z	Approved	[97]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[98]
Exemestane	DM9HPW3	Hormonally-responsive breast cancer	2C60-2C65	Approved	[99]
Goserelin	DMAT8CG	Breast cancer	2C60-2C65	Approved	[100]
Lindane	DMB8CNL	Infestations of lice and scabies	1G00.Z	Approved	[101]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[24]

Drug(s) Affected By Monoacylglycerol lipase ABHD2 (ABHD2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[4]
Selenium	DM25CGV	N. A.	N. A.	Approved	[56]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[64]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[4]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[23]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[102]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[24]
Mestranol	DMG3F94	Contraception	QA21	Approved	[4]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[4]
Bortezomib	DMNO38U	Leukemia		Approved	[103]

Drug(s) Affected By Transcriptional activator Myb (MYB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[4]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[69]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[104]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[105]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[106]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[107]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[4]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[108]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[109]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[82]

Drug(s) Affected By Myb-related protein A (MYBL1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[4]
Spironolactone	DM2AQ5N	Chronic heart failure	BD1Z	Approved	[51]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[35]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[110]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[4]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[111]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[112]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[23]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[86]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[51]

Drug(s) Affected By Tissue factor pathway inhibitor (TFPI)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[4]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[35]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[81]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[71]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[4]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[113]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[23]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[74]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[114]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[115]

Drug(s) Affected By Delta-aminolevulinic acid dehydratase (ALAD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[4]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[116]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[4]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[23]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[117]
Mestranol	DMG3F94	Contraception	QA21	Approved	[4]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[4]
Melphalan	DMOLNHF	Hematologic disease	3C0Z	Approved	[118]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[119]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[120]

Drug(s) Affected By Amphiregulin (AREG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[121]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[122]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[33]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[104]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[123]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[124]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[4]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[125]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[55]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[126]

Drug(s) Affected By CD44 antigen (CD44)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[127]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[4]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[69]
Selenium	DM25CGV	N. A.	N. A.	Approved	[128]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[129]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[130]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[131]
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[132]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[71]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[133]

Drug(s) Affected By G1/S-specific cyclin-D1 (CCND1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Indomethacin	DMSC4A7	Bursitis		Approved	[134]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[135]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[136]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[137]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[138]
Talazoparib	DM1KS78	Breast cancer	2C60-2C65	Approved	[139]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[140]
Selenium	DM25CGV	N. A.	N. A.	Approved	[56]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[141]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[142]

Drug(s) Affected By Stromal cell-derived factor 1 (CXCL12)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[143]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[4]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[144]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[145]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[146]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[71]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[4]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[147]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[148]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[149]

Drug(s) Affected By Ephrin type-A receptor 4 (EPHA4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[4]
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[150]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[81]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[71]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[4]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[55]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[38]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[23]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[24]
Mestranol	DMG3F94	Contraception	QA21	Approved	[4]

Drug(s) Affected By Single-stranded DNA-binding protein 2 (SSBP2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[4]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[81]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[71]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[151]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[38]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[74]
Mestranol	DMG3F94	Contraception	QA21	Approved	[4]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[4]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[152]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[4]

Drug(s) Affected By DNA-binding protein inhibitor ID-3 (ID3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pantothenic acid	DM091H2	Vitamin deficiency	5B55-5B71	Approved	[153]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[4]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[69]
Methimazole	DM25FL8	Hyperthyroidism	5A02	Approved	[154]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[52]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[144]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[35]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[85]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[155]
Methylprednisolone	DM4BDON	Acute adrenal insufficiency		Approved	[156]

Drug(s) Affected By Urokinase plasminogen activator surface receptor (PLAUR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[4]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[157]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[158]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[159]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[160]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[161]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[82]
Acocantherin	DM7JT24	Atrial fibrillation	BC81.3	Approved	[162]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[82]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[35]

Drug(s) Affected By Early growth response protein 3 (EGR3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[4]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[35]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[131]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[146]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[163]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[151]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[164]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[55]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[165]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[66]

Drug(s) Affected By Forkhead box protein C1 (FOXC1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[4]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[69]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[104]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[166]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[71]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[4]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[82]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[82]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[148]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[24]

Drug(s) Affected By Four and a half LIM domains protein 2 (FHL2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[80]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[69]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[167]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[32]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[4]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[151]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[55]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[82]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[82]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[66]

Drug(s) Affected By Cyclin-G2 (CCNG2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[4]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[35]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[53]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[71]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[4]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[168]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[165]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[67]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[67]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[169]

Drug(s) Affected By Kynureninase (KYNU)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[4]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[116]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[170]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[4]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[160]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[55]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[23]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[24]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[114]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[171]

Drug(s) Affected By Na(+)/H(+) exchange regulatory cofactor NHE-RF3 (PDZK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[4]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[69]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[146]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[163]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[172]
Mestranol	DMG3F94	Contraception	QA21	Approved	[4]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[88]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[173]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[173]
Estriol	DMOEM2I	Hormone deficiency	5A61.1	Approved	[173]

Drug(s) Affected By Phosphatidylinositol 3-kinase regulatory subunit gamma (PIK3R3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[4]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[174]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[32]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[4]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[92]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[66]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[23]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[24]
Mestranol	DMG3F94	Contraception	QA21	Approved	[4]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[4]

Drug(s) Affected By Dual specificity tyrosine-phosphorylation-regulated kinase 2 (DYRK2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[4]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[58]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[168]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[175]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[74]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[114]
Mestranol	DMG3F94	Contraception	QA21	Approved	[4]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[4]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[176]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[177]

Drug(s) Affected By Transcription factor AP-2 gamma (TFAP2C)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[4]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[69]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[71]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[4]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[160]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[74]
Mestranol	DMG3F94	Contraception	QA21	Approved	[4]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[62]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[178]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[4]

Drug(s) Affected By Serine/threonine-protein kinase Sgk3 (SGK3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[4]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[35]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[81]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[71]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[4]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[55]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[102]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[24]
Mestranol	DMG3F94	Contraception	QA21	Approved	[4]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[4]

Drug(s) Affected By Calmin (CLMN)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[4]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[35]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[81]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[82]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[165]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[23]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[24]
Mestranol	DMG3F94	Contraception	QA21	Approved	[4]
Sodium lauryl sulfate	DMLJ634	Constipation	DD91.1	Approved	[49]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[179]

Drug(s) Affected By DNA endonuclease RBBP8 (RBBP8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[4]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[35]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[32]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[4]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[82]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[82]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[23]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[172]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[114]
Mestranol	DMG3F94	Contraception	QA21	Approved	[4]

Drug(s) Affected By Noelin (OLFM1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[4]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[104]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[81]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[4]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[180]
Mestranol	DMG3F94	Contraception	QA21	Approved	[4]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[181]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[182]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[183]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[184]

Drug(s) Affected By Pleckstrin homology domain-containing family F member 2 (PLEKHF2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[4]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[64]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[66]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[169]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[74]
Mestranol	DMG3F94	Contraception	QA21	Approved	[4]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[4]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[119]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[185]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[186]

Drug(s) Affected By Spermine oxidase (SMOX)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[4]
Selenium	DM25CGV	N. A.	N. A.	Approved	[56]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[35]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[131]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[4]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[82]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[82]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[23]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[24]
Mestranol	DMG3F94	Contraception	QA21	Approved	[4]

Drug(s) Affected By Nicotinamide riboside kinase 1 (NMRK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[4]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[64]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[4]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[23]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[86]
Mestranol	DMG3F94	Contraception	QA21	Approved	[4]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[61]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[62]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[4]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[119]

Drug(s) Affected By Rap guanine nucleotide exchange factor-like 1 (RAPGEFL1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[4]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[4]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[55]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[38]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[66]
Mestranol	DMG3F94	Contraception	QA21	Approved	[4]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[4]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[187]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[120]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[188]

Drug(s) Affected By RNA 3'-terminal phosphate cyclase-like protein (RCL1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[4]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[69]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[32]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[4]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[189]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[169]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[24]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[171]
Mestranol	DMG3F94	Contraception	QA21	Approved	[4]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[62]

Drug(s) Affected By Estrogen receptor (ESR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[190]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[137]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[191]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[192]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[193]
Liraglutide	DM3FXPS	Non-insulin dependent diabetes	5A11	Approved	[194]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[195]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[196]
Procaine	DM4LSNE	Anaesthesia	9A78.6	Approved	[192]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[197]

Drug(s) Affected By Trefoil factor 1 (TFF1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[198]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[69]
Spironolactone	DM2AQ5N	Chronic heart failure	BD1Z	Approved	[199]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[200]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[201]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[202]
Reserpine	DM6VM38	Hypertension	BA00-BA04	Approved	[199]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[203]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[92]
Exemestane	DM9HPW3	Hormonally-responsive breast cancer	2C60-2C65	Approved	[99]

Drug(s) Affected By Nuclear receptor subfamily 1 group I member 3 (NR1I3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[204]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[205]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[206]
Artemether	DM48QOT	Malaria	1F40-1F45	Approved	[207]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[208]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[209]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[210]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[211]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[212]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[23]

Drug(s) Affected By Protein GREB1 (GREB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[213]
Spironolactone	DM2AQ5N	Chronic heart failure	BD1Z	Approved	[51]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[202]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[38]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[82]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[169]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[74]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[51]
Nandrolone	DMFWKG1	Osteoporosis	FB83.0	Approved	[199]
Mestranol	DMG3F94	Contraception	QA21	Approved	[51]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Estrogen receptor (ESR)	TTZAYWL	ESR1_HUMAN	Inhibitor	[2]
Estrogen receptor beta (ESR2)	TTOM3J0	ESR2_HUMAN	Inhibitor	[2]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Aldo-keto reductase family 1 member C1 (AKR1C1)	OTQKR4CM	AK1C1_HUMAN	Gene/Protein Processing	[3]
Aldo-keto reductase family 1 member C2 (AKR1C2)	OTQ2XMO3	AK1C2_HUMAN	Gene/Protein Processing	[3]
Aldo-keto reductase family 1 member C3 (AKR1C3)	OTU2SXBA	AK1C3_HUMAN	Gene/Protein Processing	[3]
Aldo-keto reductase family 1 member C4 (AKR1C4)	OTW2MMOF	AK1C4_HUMAN	Gene/Protein Processing	[3]
Amphiregulin (AREG)	OTJFOR67	AREG_HUMAN	Gene/Protein Processing	[4]
Calmin (CLMN)	OT7U5J3T	CLMN_HUMAN	Gene/Protein Processing	[4]
Carbonic anhydrase 12 (CA12)	OT6WNFU8	CAH12_HUMAN	Gene/Protein Processing	[4]
CD44 antigen (CD44)	OT9TTJ41	CD44_HUMAN	Gene/Protein Processing	[4]
Cyclin-G2 (CCNG2)	OTII38K2	CCNG2_HUMAN	Gene/Protein Processing	[4]
Delta-aminolevulinic acid dehydratase (ALAD)	OTHM9GSH	HEM2_HUMAN	Gene/Protein Processing	[4]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2823).
• [2] Bone targeted drugs 2. synthesis of estrogens with hydroxyapatite affinity, Bioorg. Med. Chem. Lett. 6(9):1047-1050 (1996).
• [3] Selective and potent inhibitors of human 20alpha-hydroxysteroid dehydrogenase (AKR1C1) that metabolizes neurosteroids derived from progesterone. Chem Biol Interact. 2003 Feb 1;143-144:503-13.
• [4] Moving toward integrating gene expression profiling into high-throughput testing: a gene expression biomarker accurately predicts estrogen receptor alpha modulation in a microarray compendium. Toxicol Sci. 2016 May;151(1):88-103.
• [5] Differential biochemical and cellular actions of Premarin estrogens: distinct pharmacology of bazedoxifene-conjugated estrogens combination. Mol Endocrinol. 2009 Jan;23(1):74-85.
• [6] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [7] Benzothiophene selective estrogen receptor modulators with modulated oxidative activity and receptor affinity. J Med Chem. 2007 May 31;50(11):2682-92.
• [8] Estrogen inhibits the vascular injury response in estrogen receptor beta-deficient female mice. Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15133-6.
• [9] MF101, a selective estrogen receptor beta modulator for the treatment of menopausal hot flushes: a phase II clinical trial. Menopause. 2009 May-Jun;16(3):458-65.
• [10] Company report (Axcentua)
• [11] S-equol, a potent ligand for estrogen receptor beta, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. Am J Clin Nutr. 2005 May;81(5):1072-9.
• [12] Erb-041, an estrogen receptor-beta agonist, inhibits skin photocarcinogenesis in SKH-1 hairless mice by downregulating the WNT signaling pathway. Cancer Prev Res (Phila). 2014 Feb;7(2):186-98.
• [13] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031986)
• [14] Update on alternative therapies for vulvovaginal atrophy. Patient Prefer Adherence. 2011; 5: 533-536.
• [15] Modulators of vascular sex hormone receptors and their effects in estrogen-deficiency states associated with menopause. Recent Pat Cardiovasc Drug Discov. 2008 Nov;3(3):165-86.
• [16] Reprint of Are all estrogens the same Maturitas. 2008 Sep-Oct;61(1-2):195-201.
• [17] 17alpha-Ethinylestradiol hinders nucleotide excision repair in zebrafish liver cells. Aquat Toxicol. 2009 Dec 13;95(4):273-8.
• [18] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 620).
• [19] Clinical pipeline report, company report or official report of Shionogi (2011).
• [20] Effect of selective estrogen receptor modulators on cell proliferation and estrogen receptor activities in normal human prostate stromal and epithe... Prostate Cancer Prostatic Dis. 2009;12(4):375-81.
• [21] Initro CAPE inhibitory activity towards human AKR1C3 and the molecular basis. Chem Biol Interact. 2016 Jun 25;253:60-5.
• [22] Substrate specificity of human 3(20)alpha-hydroxysteroid dehydrogenase for neurosteroids and its inhibition by benzodiazepines. Biol Pharm Bull. 2002 Apr;25(4):441-5.
• [23] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [24] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [25] Chenodeoxycholic acid significantly impacts the expression of miRNAs and genes involved in lipid, bile acid and drug metabolism in human hepatocytes. Life Sci. 2016 Jul 1;156:47-56.
• [26] Antineoplastic effects of gamma linolenic Acid on hepatocellular carcinoma cell lines. J Clin Biochem Nutr. 2010 Jul;47(1):81-90.
• [27] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [28] Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs. Chem Biol Interact. 2009 Mar 16;178(1-3):221-7.
• [29] Progestins as inhibitors of the human 20-ketosteroid reductases, AKR1C1 and AKR1C3. Chem Biol Interact. 2011 May 30;191(1-3):227-33.
• [30] In-vivo effects of simvastatin and rosuvastatin on global gene expression in peripheral blood leucocytes in a human inflammation model. Pharmacogenet Genomics. 2008 Feb;18(2):109-20.
• [31] AKR1C3 as a potential target for the inhibitory effect of dietary flavonoids. Chem Biol Interact. 2009 Mar 16;178(1-3):138-44.
• [32] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [33] Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
• [34] A new in vitro method for identifying chemical sensitizers combining peptide binding with ARE/EpRE-mediated gene expression in human skin cells. Cutan Ocul Toxicol. 2010 Sep;29(3):171-92.
• [35] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [36] Aberrantly expressed genes in HaCaT keratinocytes chronically exposed to arsenic trioxide. Biomark Insights. 2011 Feb 8;6:7-16.
• [37] Thyroid hormone responsive genes in cultured human fibroblasts. J Clin Endocrinol Metab. 2005 Feb;90(2):936-43.
• [38] The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
• [39] Progestin effects on expression of AKR1C1-AKR1C3, SRD5A1 and PGR in the Z-12 endometriotic epithelial cell line. Chem Biol Interact. 2013 Feb 25;202(1-3):218-25.
• [40] Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenase. Cancer Res. 1999 Feb 1;59(3):607-14.
• [41] Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Cancer Sci. 2007 Jun;98(6):890-9.
• [42] Initro inhibition of AKR1Cs by sulphonylureas and the structural basis. Chem Biol Interact. 2015 Oct 5;240:310-5.
• [43] Inhibition of human phenol and estrogen sulfotransferase by certain non-steroidal anti-inflammatory agents. Curr Drug Metab. 2006 Oct;7(7):745-53.
• [44] Methotrexate induction of human sulfotransferases in Hep G2 and Caco-2 cells. J Appl Toxicol. 2005 Sep-Oct;25(5):354-60.
• [45] Development and validation of a fluorescence HPLC-based screening assay for inhibition of human estrogen sulfotransferase. Anal Biochem. 2006 Oct 1;357(1):85-92.
• [46] Solvent effect on cDNA-expressed human sulfotransferase (SULT) activities in vitro. Drug Metab Dispos. 2003 Nov;31(11):1300-5.
• [47] Folic acid supplementation dysregulates gene expression in lymphoblastoid cells--implications in nutrition. Biochem Biophys Res Commun. 2011 Sep 9;412(4):688-92. doi: 10.1016/j.bbrc.2011.08.027. Epub 2011 Aug 16.
• [48] Omics-based responses induced by bosentan in human hepatoma HepaRG cell cultures. Arch Toxicol. 2018 Jun;92(6):1939-1952.
• [49] CXCL14 downregulation in human keratinocytes is a potential biomarker for a novel in vitro skin sensitization test. Toxicol Appl Pharmacol. 2020 Jan 1;386:114828. doi: 10.1016/j.taap.2019.114828. Epub 2019 Nov 14.
• [50] A novel, integrated in vitro carcinogenicity test to identify genotoxic and non-genotoxic carcinogens using human lymphoblastoid cells. Arch Toxicol. 2018 Feb;92(2):935-951. doi: 10.1007/s00204-017-2102-y. Epub 2017 Nov 6.
• [51] A Gene Expression Biomarker Identifies Chemical Modulators of Estrogen Receptor in an MCF-7 Microarray Compendium. Chem Res Toxicol. 2021 Feb 15;34(2):313-329. doi: 10.1021/acs.chemrestox.0c00243. Epub 2021 Jan 6.
• [52] Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity. Toxicology. 2014 Jan 6;315:8-16. doi: 10.1016/j.tox.2013.10.009. Epub 2013 Nov 6.
• [53] Transcriptome-based functional classifiers for direct immunotoxicity. Arch Toxicol. 2014 Mar;88(3):673-89.
• [54] Gene expression profile of multiple myeloma cell line treated by arsenic trioxide. J Huazhong Univ Sci Technolog Med Sci. 2007 Dec;27(6):646-9. doi: 10.1007/s11596-007-0606-z.
• [55] THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
• [56] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [57] Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2716-23.
• [58] Retinoic acid receptor alpha amplifications and retinoic acid sensitivity in breast cancers. Clin Breast Cancer. 2013 Oct;13(5):401-8.
• [59] Aspirin inhibits MMP-9 mRNA expression and release via the PPARalpha/gamma and COX-2/mPGES-1-mediated pathways in macrophages derived from THP-1 cells. Biomed Pharmacother. 2010 Feb;64(2):118-23. doi: 10.1016/j.biopha.2009.04.033. Epub 2009 Oct 17.
• [60] Repurposing L-menthol for systems medicine and cancer therapeutics? L-menthol induces apoptosis through caspase 10 and by suppressing HSP90. OMICS. 2016 Jan;20(1):53-64.
• [61] Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma. Cancer Res. 2023 Jan 18;83(2):181-194. doi: 10.1158/0008-5472.CAN-22-1029.
• [62] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [63] Integrated assessment by multiple gene expression analysis of quercetin bioactivity on anticancer-related mechanisms in colon cancer cells in vitro. Eur J Nutr. 2005 Mar;44(3):143-56. doi: 10.1007/s00394-004-0503-1. Epub 2004 Apr 30.
• [64] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [65] Expression profile analysis of human peripheral blood mononuclear cells in response to aspirin. Arch Immunol Ther Exp (Warsz). 2005 Mar-Apr;53(2):151-8.
• [66] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [67] Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
• [68] Targeting hypoxic tumor cell viability with carbohydrate-based carbonic anhydrase IX and XII inhibitors. J Med Chem. 2011 Oct 13;54(19):6905-18.
• [69] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [70] Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
• [71] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [72] Design, synthesis, and biological evaluation of novel carbohydrate-based sulfamates as carbonic anhydrase inhibitors. J Med Chem. 2011 Mar 10;54(5):1481-9.
• [73] DNA microarray analysis of vitamin D-induced gene expression in a human colon carcinoma cell line. Physiol Genomics. 2004 Apr 13;17(2):122-9. doi: 10.1152/physiolgenomics.00002.2003.
• [74] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [75] The effect of quercetin nanoparticle on cervical cancer progression by inducing apoptosis, autophagy and anti-proliferation via JAK2 suppression. Biomed Pharmacother. 2016 Aug;82:595-605. doi: 10.1016/j.biopha.2016.05.029. Epub 2016 Jun 9.
• [76] MS4A3-HSP27 target pathway reveals potential for haematopoietic disorder treatment in alimentary toxic aleukia. Cell Biol Toxicol. 2023 Feb;39(1):201-216. doi: 10.1007/s10565-021-09639-4. Epub 2021 Sep 28.
• [77] Paroxetine modulates immune responses by activating a JAK2/STAT3 signaling pathway. J Biochem Mol Toxicol. 2020 May;34(5):e22464. doi: 10.1002/jbt.22464. Epub 2020 Feb 5.
• [78] A comprehensive analysis of Wnt/beta-catenin signaling pathway-related genes and crosstalk pathways in the treatment of As2O3 in renal cancer. Ren Fail. 2018 Nov;40(1):331-339.
• [79] Amlodipine inhibits cell proliferation via PKD1-related pathway. Biochem Biophys Res Commun. 2008 May 2;369(2):376-81. doi: 10.1016/j.bbrc.2008.02.075. Epub 2008 Feb 25.
• [80] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [81] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [82] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [83] Cdk4/6 inhibition induces epithelial-mesenchymal transition and enhances invasiveness in pancreatic cancer cells. Mol Cancer Ther. 2012 Oct;11(10):2138-48. doi: 10.1158/1535-7163.MCT-12-0562. Epub 2012 Aug 6.
• [84] Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022 Aug 15;449:116110. doi: 10.1016/j.taap.2022.116110. Epub 2022 Jun 7.
• [85] Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
• [86] The neuroprotective action of the mood stabilizing drugs lithium chloride and sodium valproate is mediated through the up-regulation of the homeodomain protein Six1. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):124-34.
• [87] Mifepristone induced progesterone withdrawal reveals novel regulatory pathways in human endometrium. Mol Hum Reprod. 2007 Sep;13(9):641-54.
• [88] Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
• [89] Impact of selective serotonin reuptake inhibitors on neural crest stem cell formation. Toxicol Lett. 2017 Nov 5;281:20-25. doi: 10.1016/j.toxlet.2017.08.012. Epub 2017 Aug 24.
• [90] Activation of PPAR and inhibition of cell proliferation reduces key proteins associated with the basal subtype of bladder cancer in As3+-transformed UROtsa cells. PLoS One. 2020 Aug 21;15(8):e0237976. doi: 10.1371/journal.pone.0237976. eCollection 2020.
• [91] Constitutive gene expression predisposes morphogen-mediated cell fate responses of NT2/D1 and 27X-1 human embryonal carcinoma cells. Stem Cells. 2007 Mar;25(3):771-8. doi: 10.1634/stemcells.2006-0271. Epub 2006 Nov 30.
• [92] Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
• [93] Effects of the environmental estrogens bisphenol A, o,p'-DDT, p-tert-octylphenol and coumestrol on apoptosis induction, cell proliferation and the expression of estrogen sensitive molecular parameters in the human breast cancer cell line MCF-7. J Steroid Biochem Mol Biol. 2002 Jan;80(1):61-70. doi: 10.1016/s0960-0760(01)00173-x.
• [94] Conception and pharmacodynamic profile of drospirenone. Steroids. 2003 Nov;68(10-13):891-905. doi: 10.1016/j.steroids.2003.08.008.
• [95] Biological activity of all-trans-retinoic acid with and without tamoxifen and alpha-interferon 2a in breast cancer patients. Int J Oncol. 2000 Nov;17(5):991-1000. doi: 10.3892/ijo.17.5.991.
• [96] Estrogen-induced loss of progesterone receptor expression in normal and malignant ovarian surface epithelial cells. Oncogene. 2005 Jun 23;24(27):4388-400. doi: 10.1038/sj.onc.1208623.
• [97] Tibolone and its metabolites enhance tissue factor and PAI-1 expression in human endometrial stromal cells: Evidence of progestogenic effects. Steroids. 2005 Nov;70(12):840-5. doi: 10.1016/j.steroids.2005.04.010.
• [98] Expression of estrogen-, progesterone-, and androgen-responsive genes in MCF-7 and MDA-MB-231 cells treated with o,p'-DDT, p,p'-DDT, or endosulfan. J Biochem Mol Toxicol. 2021 Jun;35(6):1-8. doi: 10.1002/jbt.22773. Epub 2021 Mar 16.
• [99] Characterization of the weak estrogen receptor alpha agonistic activity of exemestane. Breast Cancer Res Treat. 2009 Aug;116(3):461-70. doi: 10.1007/s10549-008-0151-x. Epub 2008 Aug 3.
• [100] A comparative study of the effect of raloxifene and gosereline on uterine leiomyoma volume changes and estrogen receptor, progesterone receptor, bcl-2 and p53 expression immunohistochemically in premenopausal women. Eur J Obstet Gynecol Reprod Biol. 2007 Nov;135(1):94-103. doi: 10.1016/j.ejogrb.2006.07.042. Epub 2006 Sep 14.
• [101] Serum free BG-1 cell proliferation assay: a sensitive method for determining organochlorine pesticide estrogen receptor activation at the nanomolar range. Toxicol In Vitro. 2006 Apr;20(3):382-94. doi: 10.1016/j.tiv.2005.08.016. Epub 2005 Oct 19.
• [102] Transcriptional profiling of testosterone-regulated genes in the skeletal muscle of human immunodeficiency virus-infected men experiencing weight loss. J Clin Endocrinol Metab. 2007 Jul;92(7):2793-802. doi: 10.1210/jc.2006-2722. Epub 2007 Apr 17.
• [103] The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.
• [104] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [105] Inhibition of prostate cancer cell colony formation by the flavonoid quercetin correlates with modulation of specific regulatory genes. Clin Diagn Lab Immunol. 2004 Jan;11(1):63-9. doi: 10.1128/cdli.11.1.63-69.2004.
• [106] Peroxisome proliferator-activated receptor ligands affect growth-related gene expression in human leukemic cells. J Pharmacol Exp Ther. 2003 Jun;305(3):932-42. doi: 10.1124/jpet.103.049098. Epub 2003 Mar 20.
• [107] Comparison of the gene expression profiles of monocytic versus granulocytic lineages of HL-60 leukemia cell differentiation by DNA microarray analysis. Life Sci. 2003 Aug 15;73(13):1705-19. doi: 10.1016/s0024-3205(03)00515-0.
• [108] Hypomethylation mediated by decreased DNMTs involves in the activation of proto-oncogene MPL in TK6 cells treated with hydroquinone. Toxicol Lett. 2012 Mar 25;209(3):239-45. doi: 10.1016/j.toxlet.2011.12.020. Epub 2012 Jan 8.
• [109] Thalidomide alters c-MYB and PIM-1 signaling in K-562 cells. Pharmacol Res. 2006 Aug;54(2):91-6. doi: 10.1016/j.phrs.2006.02.010. Epub 2006 Mar 8.
• [110] Development and validation of the TGx-HDACi transcriptomic biomarker to detect histone deacetylase inhibitors in human TK6 cells. Arch Toxicol. 2021 May;95(5):1631-1645. doi: 10.1007/s00204-021-03014-2. Epub 2021 Mar 26.
• [111] Changes in gene expression profiles of multiple myeloma cells induced by arsenic trioxide (ATO): possible mechanisms to explain ATO resistance in vivo. Br J Haematol. 2005 Mar;128(5):636-44.
• [112] Single-cell Transcriptome Mapping Identifies Common and Cell-type Specific Genes Affected by Acute Delta9-tetrahydrocannabinol in Humans. Sci Rep. 2020 Feb 26;10(1):3450. doi: 10.1038/s41598-020-59827-1.
• [113] Mitogen-activated protein kinases pathway is involved in physiological testosterone-induced tissue factor pathway inhibitor expression in endothelial cells. Blood Coagul Fibrinolysis. 2010 Jul;21(5):420-4. doi: 10.1097/MBC.0b013e328337b475.
• [114] Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
• [115] Gene expression signatures after ethanol exposure in differentiating embryoid bodies. Toxicol In Vitro. 2018 Feb;46:66-76.
• [116] Oxidative stress modulates theophylline effects on steroid responsiveness. Biochem Biophys Res Commun. 2008 Dec 19;377(3):797-802.
• [117] A genomic approach to predict synergistic combinations for breast cancer treatment. Pharmacogenomics J. 2013 Feb;13(1):94-104. doi: 10.1038/tpj.2011.48. Epub 2011 Nov 15.
• [118] delta-Aminolevulinate dehydratase activity and oxidative stress during melphalan and cyclophosphamide-BCNU-etoposide (CBV) conditioning regimens in autologous bone marrow transplantation patients. Pharmacol Res. 2009 Apr;59(4):279-84.
• [119] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [120] Acute hypersensitivity of pluripotent testicular cancer-derived embryonal carcinoma to low-dose 5-aza deoxycytidine is associated with global DNA Damage-associated p53 activation, anti-pluripotency and DNA demethylation. PLoS One. 2012;7(12):e53003. doi: 10.1371/journal.pone.0053003. Epub 2012 Dec 27.
• [121] Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
• [122] Analysis of estrogen agonism and antagonism of tamoxifen, raloxifene, and ICI182780 in endometrial cancer cells: a putative role for the epidermal growth factor receptor ligand amphiregulin. J Soc Gynecol Investig. 2005 Oct;12(7):e55-67.
• [123] Ligand-dependent activation of the epidermal growth factor receptor by secondary bile acids in polarizing colon cancer cells. Surgery. 2005 Sep;138(3):415-21. doi: 10.1016/j.surg.2005.06.030.
• [124] Retinoid-induced epidermal hyperplasia is mediated by epidermal growth factor receptor activation via specific induction of its ligands heparin-binding EGF and amphiregulin in human skin in vivo. J Invest Dermatol. 2006 Apr;126(4):732-9. doi: 10.1038/sj.jid.5700202.
• [125] Effects of chlorpromazine with and without UV irradiation on gene expression of HepG2 cells. Mutat Res. 2005 Aug 4;575(1-2):47-60. doi: 10.1016/j.mrfmmm.2005.03.002. Epub 2005 Apr 26.
• [126] Amphiregulin is a vitamin D3 target gene in squamous cell and breast carcinoma. Biochem Biophys Res Commun. 2001 Mar 9;281(4):1051-6. doi: 10.1006/bbrc.2001.4466.
• [127] Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front Physiol. 2016 Nov 24;7:559. doi: 10.3389/fphys.2016.00559. eCollection 2016.
• [128] Promotion of the articular cartilage proteoglycan degradation by T-2 toxin and selenium protective effect. J Zhejiang Univ Sci B. 2008 Jan;9(1):22-33. doi: 10.1631/jzus.B071322.
• [129] Ciprofloxacin mediates cancer stem cell phenotypes in lung cancer cells through caveolin-1-dependent mechanism. Chem Biol Interact. 2016 Apr 25;250:1-11.
• [130] Simvastatin prevents skeletal metastasis of breast cancer by an antagonistic interplay between p53 and CD44. J Biol Chem. 2011 Apr 1;286(13):11314-27. doi: 10.1074/jbc.M110.193714. Epub 2011 Jan 3.
• [131] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [132] Enhancement of the antiproliferative activity of gemcitabine by modulation of c-Met pathway in pancreatic cancer. Curr Pharm Des. 2013;19(5):940-50.
• [133] The antipsychotic chlorpromazine suppresses YAP signaling, stemness properties, and drug resistance in breast cancer cells. Chem Biol Interact. 2019 Apr 1;302:28-35. doi: 10.1016/j.cbi.2019.01.033. Epub 2019 Jan 28.
• [134] The nonsteroidal anti-inflammatory drugs aspirin and indomethacin attenuate beta-catenin/TCF-4 signaling. Oncogene. 2001 Feb 1;20(5):645-53. doi: 10.1038/sj.onc.1204123.
• [135] Novel mechanism of cannabidiol-induced apoptosis in breast cancer cell lines. Breast. 2018 Oct;41:34-41. doi: 10.1016/j.breast.2018.06.009. Epub 2018 Jun 22.
• [136] -Carotene Induces Apoptosis in Human Esophageal Squamous Cell Carcinoma Cell Lines via the Cav-1/AKT/NF-B Signaling Pathway. J Biochem Mol Toxicol. 2016 Mar;30(3):148-57. doi: 10.1002/jbt.21773. Epub 2016 Jan 6.
• [137] Cross-talk between non-genomic and genomic signalling pathways--distinct effect profiles of environmental estrogens. Toxicol Appl Pharmacol. 2010 Jun 1;245(2):160-70. doi: 10.1016/j.taap.2010.02.015. Epub 2010 Mar 4.
• [138] Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res. 2006 Jun 1;66(11):5542-8. doi: 10.1158/0008-5472.CAN-05-4620.
• [139] BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile. J Biochem Mol Toxicol. 2019 May;33(5):e22286. doi: 10.1002/jbt.22286. Epub 2019 Jan 23.
• [140] Resveratrol attenuates senescence of adipose-derived mesenchymal stem cells and restores their paracrine effects on promoting insulin secretion of INS-1 cells through Pim-1. Eur Rev Med Pharmacol Sci. 2016;20(6):1203-13.
• [141] Ribavirin augments doxorubicin's efficacy in human hepatocellular carcinoma through inhibiting doxorubicin-induced eIF4E activation. J Biochem Mol Toxicol. 2018 Jan;32(1). doi: 10.1002/jbt.22007. Epub 2017 Nov 7.
• [142] Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells. J Pharmacol Exp Ther. 2001 Sep;298(3):976-85.
• [143] Beta-carotene and apocarotenals promote retinoid signaling in BEAS-2B human bronchioepithelial cells. Arch Biochem Biophys. 2006 Nov 1;455(1):48-60.
• [144] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [145] Chemokine stromal cell-derived factor-1 induction by C/EBPbeta activation is associated with all-trans-retinoic acid-induced leukemic cell differentiation. J Leukoc Biol. 2007 Nov;82(5):1332-9. doi: 10.1189/jlb.1106697. Epub 2007 Jul 26.
• [146] Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
• [147] How benzene and its metabolites affect human marrow derived mesenchymal stem cells. Toxicol Lett. 2012 Oct 17;214(2):145-53. doi: 10.1016/j.toxlet.2012.08.015. Epub 2012 Aug 30.
• [148] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [149] Sevoflurane but not propofol enhances ovarian cancer cell biology through regulating cellular metabolic and signaling mechanisms. Cell Biol Toxicol. 2023 Aug;39(4):1395-1411. doi: 10.1007/s10565-022-09766-6. Epub 2022 Oct 8.
• [150] The platelet P2Y12 receptor contributes to granule secretion through Ephrin A4 receptor. Platelets. 2012;23(8):617-25. doi: 10.3109/09537104.2011.645924. Epub 2012 Jan 24.
• [151] Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration. Arch Toxicol. 2016 Jan;90(1):159-80.
• [152] The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia. 2009 Jun;23(6):1019-28.
• [153] Calcium pantothenate modulates gene expression in proliferating human dermal fibroblasts. Exp Dermatol. 2009 Nov;18(11):969-78. doi: 10.1111/j.1600-0625.2009.00884.x. Epub 2009 Apr 8.
• [154] Monitoring of deiodinase deficiency based on transcriptomic responses in SH-SY5Y cells. Arch Toxicol. 2013 Jun;87(6):1103-13. doi: 10.1007/s00204-013-1018-4. Epub 2013 Feb 10.
• [155] Expression of the helix-loop-helix protein inhibitor of DNA binding-1 (ID-1) is activated by all-trans retinoic acid in normal human keratinocytes. Toxicol Appl Pharmacol. 2006 Aug 1;214(3):219-29. doi: 10.1016/j.taap.2005.12.015. Epub 2006 Feb 21.
• [156] Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
• [157] Nicotine stimulates urokinase-type plasminogen activator receptor expression and cell invasiveness through mitogen-activated protein kinase and reactive oxygen species signaling in ECV304 endothelial cells. Toxicol Appl Pharmacol. 2012 Mar 1;259(2):248-56. doi: 10.1016/j.taap.2012.01.002. Epub 2012 Jan 9.
• [158] Quercetin inhibits invasion, migration and signalling molecules involved in cell survival and proliferation of prostate cancer cell line (PC-3). Cell Biochem Funct. 2011 Mar;29(2):87-95. doi: 10.1002/cbf.1725. Epub 2011 Feb 9.
• [159] [Clinical study on the fibrinolytic activity in patients with acute promyelocytic leukemia]. Zhonghua Xue Ye Xue Za Zhi. 2009 Mar;30(3):145-9.
• [160] Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood. 2005 Jul 1;106(1):304-10.
• [161] Aspirin upregulates expression of urokinase type plasminogen activator receptor (uPAR) gene in human colon cancer cells through AP1. Biochem Biophys Res Commun. 2006 Sep 22;348(2):618-27. doi: 10.1016/j.bbrc.2006.07.098. Epub 2006 Jul 28.
• [162] Ouabain impairs cell migration, and invasion and alters gene expression of human osteosarcoma U-2 OS cells. Environ Toxicol. 2017 Nov;32(11):2400-2413. doi: 10.1002/tox.22453. Epub 2017 Aug 10.
• [163] Using a customized DNA microarray for expression profiling of the estrogen-responsive genes to evaluate estrogen activity among natural estrogens and industrial chemicals. Environ Health Perspect. 2004 May;112(7):773-81. doi: 10.1289/ehp.6753.
• [164] Keratinocyte-derived IL-36gama plays a role in hydroquinone-induced chemical leukoderma through inhibition of melanogenesis in human epidermal melanocytes. Arch Toxicol. 2019 Aug;93(8):2307-2320.
• [165] Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
• [166] The RET oncogene is a critical component of transcriptional programs associated with retinoic acid-induced differentiation in neuroblastoma. Mol Cancer Ther. 2007 Apr;6(4):1300-9.
• [167] Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
• [168] Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
• [169] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [170] Effect of retinoic acid on gene expression in human conjunctival epithelium: secretory phospholipase A2 mediates retinoic acid induction of MUC16. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4050-61.
• [171] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [172] Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
• [173] Identification of estrogen-responsive genes by complementary deoxyribonucleic acid microarray and characterization of a novel early estrogen-induced gene: EEIG1. Mol Endocrinol. 2004 Feb;18(2):402-11. doi: 10.1210/me.2003-0202. Epub 2003 Nov 6.
• [174] Quercetin induced cell apoptosis and altered gene expression in AGS human gastric cancer cells. Environ Toxicol. 2018 Nov;33(11):1168-1181. doi: 10.1002/tox.22623. Epub 2018 Aug 27.
• [175] Delta9-tetrahydrocannabinol inhibits cytotrophoblast cell proliferation and modulates gene transcription. Mol Hum Reprod. 2006 May;12(5):321-33. doi: 10.1093/molehr/gal036. Epub 2006 Apr 5.
• [176] In vitro and in vivo irinotecan-induced changes in expression profiles of cell cycle and apoptosis-associated genes in acute myeloid leukemia cells. Mol Cancer Ther. 2005 Jun;4(6):885-900.
• [177] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [178] Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 2009 Aug 21;138(4):645-659. doi: 10.1016/j.cell.2009.06.034. Epub 2009 Aug 13.
• [179] Identification of mechanisms of action of bisphenol a-induced human preadipocyte differentiation by transcriptional profiling. Obesity (Silver Spring). 2014 Nov;22(11):2333-43.
• [180] Effects of lithium and valproic acid on gene expression and phenotypic markers in an NT2 neurosphere model of neural development. PLoS One. 2013;8(3):e58822.
• [181] Gene expression profiling in Ishikawa cells: a fingerprint for estrogen active compounds. Toxicol Appl Pharmacol. 2009 Apr 1;236(1):85-96.
• [182] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [183] Dissecting progressive stages of 5-fluorouracil resistance in vitro using RNA expression profiling. Int J Cancer. 2004 Nov 1;112(2):200-12. doi: 10.1002/ijc.20401.
• [184] Convergent transcriptional profiles induced by endogenous estrogen and distinct xenoestrogens in breast cancer cells. Carcinogenesis. 2006 Aug;27(8):1567-78.
• [185] Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells. Biomark Insights. 2016 Aug 24;11:113-21.
• [186] Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
• [187] DNA methylation inhibits p53-mediated survivin repression. Oncogene. 2009 May 14;28(19):2046-50. doi: 10.1038/onc.2009.62. Epub 2009 Apr 13.
• [188] Persistent and non-persistent changes in gene expression result from long-term estrogen exposure of MCF-7 breast cancer cells. J Steroid Biochem Mol Biol. 2011 Feb;123(3-5):140-50.
• [189] Endoplasmic reticulum stress contributes to arsenic trioxide-induced intrinsic apoptosis in human umbilical and bone marrow mesenchymal stem cells. Environ Toxicol. 2016 Mar;31(3):314-28.
• [190] Estrogen-like activity of metals in MCF-7 breast cancer cells. Endocrinology. 2003 Jun;144(6):2425-36. doi: 10.1210/en.2002-221054.
• [191] Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Res Treat. 2006 Mar;96(2):131-46. doi: 10.1007/s10549-005-9070-2. Epub 2005 Oct 27.
• [192] Sensitivity of human dental pulp cells to eighteen chemical agents used for endodontic treatments in dentistry. Odontology. 2013 Jan;101(1):43-51.
• [193] The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res. 2005 Jan 1;65(1):18-25.
• [194] Antitumoral activity of liraglutide, a new DNMT inhibitor in breast cancer cells in vitro and in vivo. Chem Biol Interact. 2021 Nov 1;349:109641. doi: 10.1016/j.cbi.2021.109641. Epub 2021 Sep 14.
• [195] Estrogen receptor alpha mediates the proliferative but not the cytotoxic dose-dependent effects of two major phytoestrogens on human breast cancer cells. Mol Pharmacol. 2001 Sep;60(3):595-602.
• [196] Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth. Br J Cancer. 2007 Apr 23;96(8):1204-15. doi: 10.1038/sj.bjc.6603705. Epub 2007 Mar 27.
• [197] Prediction of the combined effects of multiple estrogenic chemicals on MCF-7 human breast cancer cells and a preliminary molecular exploration of the estrogenic proliferative effects and related gene expression. Ecotoxicol Environ Saf. 2018 Sep 30;160:1-9. doi: 10.1016/j.ecoenv.2018.05.025. Epub 2018 May 21.
• [198] Resveratrol modulates the phosphoinositide 3-kinase pathway through an estrogen receptor alpha-dependent mechanism: relevance in cell proliferation. Int J Cancer. 2004 Mar 20;109(2):167-73. doi: 10.1002/ijc.11720.
• [199] Evaluation of an imaging-based in vitro screening platform for estrogenic activity with OECD reference chemicals. Toxicol In Vitro. 2022 Jun;81:105348. doi: 10.1016/j.tiv.2022.105348. Epub 2022 Mar 18.
• [200] Estrogenic activities of Ginkgo biloba extracts. Life Sci. 2004 Jan 30;74(11):1325-35. doi: 10.1016/j.lfs.2003.06.045.
• [201] Tartrazine and sunset yellow are xenoestrogens in a new screening assay to identify modulators of human oestrogen receptor transcriptional activity. Toxicology. 2012 Aug 16;298(1-3):40-51. doi: 10.1016/j.tox.2012.04.014. Epub 2012 May 3.
• [202] Arsenic induces functional re-expression of estrogen receptor by demethylation of DNA in estrogen receptor-negative human breast cancer. PLoS One. 2012;7(4):e35957. doi: 10.1371/journal.pone.0035957. Epub 2012 Apr 27.
• [203] Co-culture of primary human mammary fibroblasts and MCF-7 cells as an in vitro breast cancer model. Toxicol Sci. 2005 Feb;83(2):257-63.
• [204] Identification of HMG-CoA reductase inhibitors as activators for human, mouse and rat constitutive androstane receptor. Drug Metab Dispos. 2005 Jul;33(7):924-9.
• [205] Bioactive terpenoids and flavonoids from Ginkgo biloba extract induce the expression of hepatic drug-metabolizing enzymes through pregnane X receptor, constitutive androstane receptor, and aryl hydrocarbon receptor-mediated pathways. Pharm Res. 2009 Apr;26(4):872-82.
• [206] Species-specific toxicity of diclofenac and troglitazone in primary human and rat hepatocytes. Chem Biol Interact. 2009 Apr 15;179(1):17-24.
• [207] Fetal bovine serum and human constitutive androstane receptor: evidence for activation of the SV23 splice variant by artemisinin, artemether, and arteether in a serum-free cell culture system. Toxicol Appl Pharmacol. 2014 Jun 1;277(2):221-30. doi: 10.1016/j.taap.2014.03.023. Epub 2014 Apr 12.
• [208] Constitutive androstane/active receptor is a target of retinoic acid receptor in humans. Biochem Pharmacol. 2010 Jul 1;80(1):129-35. doi: 10.1016/j.bcp.2010.02.023. Epub 2010 Mar 6.
• [209] Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury. Arch Toxicol. 2020 Apr;94(4):1151-1172. doi: 10.1007/s00204-020-02691-9. Epub 2020 Mar 10.
• [210] Expression and inducibility of cytochrome P450s (CYP1A1, 2B6, 2E1, 3A4) in human cord blood CD34(+) stem cell-derived differentiating neuronal cells. Toxicol Sci. 2012 Oct;129(2):392-410.
• [211] Agonistic effects of diverse xenobiotics on the constitutive androstane receptor as detected in a recombinant yeast-cell assay. Toxicol In Vitro. 2018 Feb;46:335-349. doi: 10.1016/j.tiv.2017.09.014. Epub 2017 Sep 18.
• [212] Teriflunomide is an indirect human constitutive androstane receptor (CAR) activator interacting with epidermal growth factor (EGF) signaling. Front Pharmacol. 2018 Oct 11;9:993.
• [213] Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.